Institution Directory

Clinical trials at UCSF

Sites in San Francisco, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1391

Shown on this page

Current sort

Stored official records

Conditions: Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Synchronous Bilateral Breast Carcinoma
Interventions: Health Education Program, Weight Loss Intervention; Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3,177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 1464
States / cities: Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 921 more

Conditions: Prostatic Neoplasms
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 21 Years and older · Male only
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2032
U.S. locations: 10
States / cities: San Francisco, California • Stanford, California • Atlanta, Georgia + 5 more

Conditions: Any Conditions That Are Genetic or Suspected to be Genetic in Origin
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2050
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Angiosarcoma, Angiosarcoma, Adult
Interventions: Pembrolizumab, Vusolimogene Oderparepvec (VO); Drug · Biological
Lead sponsor: Varun Monga, MBBS; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cardiac Magnetic Resonance Imaging, Ischemic Heart Disease (IHD), Myocardial Blood Flow
Interventions: Blood draw for the laboratory assessment, Gadavist, Qualitative Myocardial Blood Flow Evaluation, Quantitative Myocardial Blood Flow Evaluation, Vasodilator; Diagnostic Test · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 35 Years to 85 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 13
States / cities: San Francisco, California • Louisville, Kentucky • Boston, Massachusetts + 9 more

Conditions: Advanced or Metastatic Solid Tumors, Brain Neoplasms, Differentiated Thyroid Cancer, Glioma, HGG, High Grade Glioma, LGG, Low Grade Glioma, Malignant Neoplasms, Melanoma, NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, Thyroid Cancer
Interventions: PF-07799544, PF-07799933; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 44
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Rogers, Arkansas + 22 more

Conditions: Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Interventions: VX-017, VX-880; Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 12
States / cities: Duarte, California • San Francisco, California • Miami, Florida + 8 more

Conditions: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Interventions: 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Vincristine Sulfate; Radiation · Drug · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 30 Years
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 211
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 151 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Abatacept, Rituximab-pvvr, Sterile Sodium Chloride; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 8 Years to 45 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 17
States / cities: Orange, California • Palo Alto, California • San Francisco, California + 14 more

Conditions: Metastatic Urothelial Cancer
Interventions: Avelumab, Carboplatin, Cisplatin, Domvanalimab, Enfortumab Vedotin, Gemcitabine, Pembrolizumab, Sacituzumab Govitecan-hziy, Zimberelimab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 30
States / cities: Tucson, Arizona • San Francisco, California • Littleton, Colorado + 25 more

Conditions: Metastatic Prostate Cancer
Interventions: Tarlatamab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • Basking Ridge, New Jersey + 7 more

Conditions: Blood Protein Disorders, Gene Therapy, Hematologic Disease and Disorders, Hemostatic Disorders, Immune System Disease, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma Progression, Multiple Myeloma in Relapse, Myeloma Multiple, Neoplasm, Neoplasms by Histologic Type, Paraproteinemias, Vascular Disorder
Interventions: KLN-1010; Drug
Lead sponsor: Kelonia Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2042
U.S. locations: 8
States / cities: Duarte, California • Palo Alto, California • San Francisco, California + 5 more

About this UCSF institution page

What this page lists: ClinicalTrials.gov records that list UCSF in San Francisco, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UCSF

Filter and sort this campus

Stored official records

Breast Cancer WEight Loss Study (BWEL Study)

Prostate Active Surveillance Study

UCSF Center for Genome Surgery Biobank and Registry

Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma

The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

A Study of Tarlatamab for People With Prostate Cancer

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

About this UCSF institution page